Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults-Reference-Cited by-同舟云学术

Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults

Published:2022-01-25 Issue:2 Volume:1 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Caraco Yoseph¹,Crofoot Gordon E.²,Moncada Pablo Andres³,Galustyan Anna Nikolaevna⁴⁵,Musungaie Dany Badibanga⁶,Payne Brendan⁷,Kovalchuk Evgeniy⁸,Gonzalez Antonio⁹,Brown Michelle L.¹⁰,Williams-Diaz Angela¹⁰,Gao Wei¹⁰,Strizki Julie M.¹⁰,Grobler Jay¹⁰,Du Jiejun¹⁰,Assaid Christopher A.¹⁰,Paschke Amanda¹⁰,Butterton Joan R.¹⁰,Johnson Matthew G.¹⁰,De Anda Carisa¹⁰

Affiliation:

1. Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

2. Crofoot Research Center, Inc., Houston, TX

3. Department of Internal Medicine, Infectious Disease Service, Fundación Valle del Lili, Cali, Colombia

4. Saint Petersburg State Pediatric Medical University, Saint Petersburg, Russia

5. Strategic Medical System LLC, Saint Petersburg, Russia

6. Jongaie Research, Gauteng, South Africa

7. Departments of Infectious Diseases and Medical Virology, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK

8. Medical Research Institute LLC, Saint Petersburg, Russia

9. Advanced Research for Health Improvement LLC, Immokalee, FL

10. Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ

Publisher

Massachusetts Medical Society

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study;Age and Ageing;2024-08

2. Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand;International Journal of Infectious Diseases;2024-06

3. Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis;Journal of Microbiology, Immunology and Infection;2024-06

4. Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: a systematic review and meta-analysis;The Lancet Microbe;2024-05

5. Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study;Journal of Medical Virology;2024-05